Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.
about
Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraintsKilling me softly--future challenges in apoptosis researchEnhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive LiposomesIntroducing lasso peptides as molecular scaffolds for drug design: engineering of an integrin antagonistThe cyclic cystine ladder of theta-defensins as a stable, bifunctional scaffold: A proof-of-concept study using the integrin-binding RGD motifIntegrins in the Spotlight of CancerMotif mediated protein-protein interactions as drug targetsPeptide Conjugation to a Polymer Coating via Native Chemical Ligation of Azlactones for Cell CultureConstraining cyclic peptides to mimic protein structure motifs.β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapyOncologic Angiogenesis Imaging in the clinic---how and why.Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrinAdverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Effects of the RGD loop and C-terminus of rhodostomin on regulating integrin αIIbβ3 recognition.Uptake and transfection efficiency of PEGylated cationic liposome-DNA complexes with and without RGD-tagging.Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repairCellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.Monocyte adhesion to atherosclerotic matrix proteins is enhanced by Asn-Gly-Arg deamidationIncreasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation.Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds.An easily accessible sulfated saccharide mimetic inhibits in vitro human tumor cell adhesion and angiogenesis of vascular endothelial cells.Cationic liposome-nucleic acid complexes for gene delivery and gene silencing.Sulfated Escherichia coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III.Cyclic peptides as therapeutic agents and biochemical tools.Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cellsDevelopment of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential.Ex vivo engineered immune organoids for controlled germinal center reactions.Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.Hitting a Moving Target: How Does an N-Methyl Group Impact Biological Activity?Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin CleavageIminoboronate-Based Peptide Cyclization That Responds to pH, Oxidation, and Small Molecule Modulators.Importance of interaction between nerve growth factor and α9β1 integrin in glial tumor angiogenesisInsights into the Binding of Cyclic RGD Peptidomimetics to α5β1 Integrin by using Live-Cell NMR And Computational Studies.Canstatin inhibits hypoxia-induced apoptosis through activation of integrin/focal adhesion kinase/Akt signaling pathway in H9c2 cardiomyoblasts.Structural determinants of integrin β-subunit specificity for latent TGF-β.In vitro and in vivo drug disposition of cilengitide in animals and human.Rational design of a protein that binds integrin αvβ3 outside the ligand binding site.Human neural stem cell-induced endothelial morphogenesis requires autocrine/paracrine and juxtacrine signaling.Antagonizing Integrin β3 Increases Immunosuppression in Cancer.Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours
P2860
Q27021652-7C877130-EEC3-4E49-A6C9-33B522AF5FBBQ27025213-0BD900C3-46EF-4A08-907C-004B5D79E0DFQ27314854-1143FAF2-DBBB-46C5-968B-4FD0EA7A8AA4Q27671423-E33F2546-40C6-4A7F-8DC8-E9D12F31D0E0Q27688055-B2DFB40C-ACAA-43FD-BCD0-7EBC7F0EE542Q28066805-DBA2A08E-7A8C-4D74-AFB1-95034EA44DECQ28079554-E54CC5FB-948E-49B0-BD88-8188C3DDFC18Q28816974-EAABF36E-BC69-4A3E-B24D-93419FCF9256Q30367509-4725B33B-DDA1-4474-B516-FA6904D453A8Q30427521-6BEF6067-5EEC-4954-9185-3D0005D3E906Q30472751-360ADA8C-9439-4822-AB57-DA3AD62A5420Q30528396-5048AA97-6B69-4610-9288-29B06F1C08C2Q33410375-183FE6B1-393B-442D-87F6-2B66297B4DFBQ33554510-5DA09D78-9D3C-4D22-9FED-FDFEDD7158B5Q33654083-A7773188-1CAF-44E2-8518-69AF7E83989AQ33709432-A5057695-A163-4A3E-BA80-7C905A0F2533Q33840143-8C3DE34D-1A26-4AC0-8B38-38917C64DD84Q33916089-DB23CCA8-1C0E-4623-9397-93DCB9A56AE5Q34030885-D9EE438D-9CF9-4E07-9588-8A04E24C6E48Q34123096-23498525-91DC-4E90-BF80-F6D6D73ABA13Q34422665-18CD54FE-1CF7-42A0-A533-09C2EF74FD11Q34889277-D4648E6E-8A2A-4DA7-B86C-74761A0E0B07Q34981768-28747A64-B064-4365-A11E-51719E866614Q35015231-271A20B2-449F-42CB-B064-AD7AD2EA9550Q35029454-E22ECC65-8D6A-46E2-8926-C9C2E36F13F5Q35089514-D1D2A0A9-2DF6-46A8-B9D6-B47C3DA42813Q35812007-E05751C7-A062-4F6E-8ACB-CD5E9714A820Q35864258-D853218C-F4D3-434C-977D-8EF70B2A334AQ35902732-3B7526C2-AD52-494D-9981-AE01AEB2121AQ35913508-98E331CA-9D42-4AC1-B77C-070034DB62D5Q35917996-2CCEC0ED-C233-47A1-85D0-FE1D55C5FCB2Q36048205-A218B990-23A1-4FD7-AD47-80D26CB27423Q36272448-E2868966-BF0F-449E-A8C6-3D6A532C602DQ36290081-F6C426C1-1269-4882-8EDA-6E9F51BED6ADQ36476329-538845C2-8F70-44FC-9664-778F1FDC8C93Q36719621-FBDB41FB-3CA4-4A2B-B0FC-8D47C92670F8Q36974007-FC1DCC44-974E-44AE-B9BC-C52A58FE385FQ37061645-2F14F345-C12F-4B00-AD9A-8C2561E6C2A4Q37094368-6F35B5AE-61D0-4BB5-A4B0-D418D04EC723Q37096002-D4F7D41C-B937-4754-B849-94A369520F3F
P2860
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Cilengitide: the first anti-an ...... hesis and clinical evaluation.
@ast
Cilengitide: the first anti-an ...... hesis and clinical evaluation.
@en
type
label
Cilengitide: the first anti-an ...... hesis and clinical evaluation.
@ast
Cilengitide: the first anti-an ...... hesis and clinical evaluation.
@en
prefLabel
Cilengitide: the first anti-an ...... hesis and clinical evaluation.
@ast
Cilengitide: the first anti-an ...... hesis and clinical evaluation.
@en
P2093
P2860
P921
P1476
Cilengitide: the first anti-an ...... hesis and clinical evaluation.
@en
P2093
Carlos Mas-Moruno
Florian Rechenmacher
Horst Kessler
P2860
P304
P356
10.2174/187152010794728639
P5008
P577
2010-12-01T00:00:00Z